Motus GI Holdings, Inc.: Nasdaq/NYSE listing notice — Motus GI receives Nasdaq delisting notice for bid price non-compliance; cure period to Sept 27, 2023

Motus GI Holdings, Inc.

Received Nasdaq notice on March 31, 2023 for failing to maintain $1.00 minimum bid price over 30 consecutive business days.
Has 180 calendar days, until September 27, 2023, to regain compliance.
Compliance requires closing bid price at or above $1.00 for at least ten consecutive business days.
If not cured, may seek additional 180-day period by meeting other listing requirements and effecting reverse stock split.
Company is evaluating options to regain compliance; no immediate delisting effect.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Motus GI Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 31, 2023, Motus GI Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-23-011021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.